Year-end Report 2012
Continued growth in clinical sales, +55% in the fourth quarter supported by US operations and signed distribution agreements in key regions.January – December 2012 · Global Net sales grew by 57% to SEK 147.0m (93.5)* of which SEK 35.7m (15.5) were strategic sales (sales to Pharmaceutical companies and CRO’s for clinical trials). Adjusted for currency fluctuations, net sales rose by 56% Year over Year (Y-o-Y). · The worldwide number of NIOX MINO® repeat tests sold increased in total by 35%; repeat tests for clinical use in the US grew by 54%. Total number of tests sold (repeat and